Clinical experience with talimogene laherparepvec in a melanoma population at a university based cancer center.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21547
Abstract: e21547Background: Talimogene laherparepvec (Imlygic or T-VEC) is a first-in-class oncolytic virus that received FDA approval for recurrent unresectable melanoma based on the OPTiM trial. Since its ... read more here.
Keywords: talimogene laherparepvec; experience talimogene; talimogene; clinical experience ... See more keywords